<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3291">
  <stage>Registered</stage>
  <submitdate>11/08/2011</submitdate>
  <approvaldate>11/08/2011</approvaldate>
  <nctid>NCT01431937</nctid>
  <trial_identification>
    <studytitle>Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers</studytitle>
    <scientifictitle>A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym>P1A114347</trialacronym>
    <secondaryid>114347</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Sclerosis, Relapsing-Remitting</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK2018682
Treatment: drugs - Placebo

Active Comparator: GSK2018682 - Active Drug

Placebo Comparator: Placebo Control - Placebo


Treatment: drugs: GSK2018682
Active Drug

Treatment: drugs: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate the safety and tolerability of repeat oral doses of GSK2018682 in healthy volunteers (males and females of non-childbearing potential) - Adverse event monitoring, Laboratory parameters (haematology, clinical chemistry, urinalysis), Ophthalmic examination</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To investigate effects of repeat oral doses of GSK2018682 on heart rate and blood pressure in healthy volunteers - 12-lead ECG, Telemetry ECG, Holter ECG, Vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature), Ambulatory blood pressure monitoring</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To investigate effects of repeat oral doses of GSK2018682 on lung function in healthy volunteers - FEV1 obtained via spirometry</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To investigate the pharmacokinetics of repeat oral doses of GSK2018682 in healthy volunteers - Peak blood concentration, Time of peak blood concentration, Area under the blood concentration-time curve over the 24-hour dose interval and area under the blood concentration-time curve from time-zero extrapolated to infinite time, Accumulation ratio, Terminal half-life, Apparent oral clearance, Through concentration</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To characterize the metabolism of GSK2018682 - GSK2018682 bile metabolites, GSK2018682 whole blood metabolites</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Evaluate the effect of repeat oral doses of GSK2018682 on lymphocytes in healthy volunteers - % Change from baseline in absolute lymphocyte counts (ALC), % Change from baseline in subsets CD3+ [CD4+ and CD8+], CD19+, CD16+/CD56+ counts, % Change from baseline in further defined functional T cell subsets (naïve, central memory, effector memory and regulatory T cells)</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To explore the PK/PD relationship between blood concentrations and changes in vital signs and ECG parameters - PK/PD model with parameters of the models will be determined that best describe the relationship between blood concentrations of GSK2018682 and vital signs and ECG parameters</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To explore the PK/PD relationship between blood concentrations of GSK2018682 and reduction in lymphocyte counts - PK/PD model with parameters of the models will be determined that best describe the relationship between blood concentrations of GSK2018682 and reduction ALC and subset counts CD3+ [CD4+ and CD8+], CD19+, CD16+/CD56+ and further defined functional T cell subsets (naïve, central memory, effector memory and regulatory T cells)</outcome>
      <timepoint>Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 13 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             cardiac monitoring.

          -  Females must be of non-childbearing potential.

          -  BMI within the range 19 - 29 kg/m2 (inclusive).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for HIV antibody.

          -  History of regular alcohol consumption within 6 months of the study.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, unless in the opinion of the Investigator and GSK Medical
             Monitor the medication will not interfere with the study procedures or compromise
             subject safety.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Were participation in the study would result in donation of blood or blood products in
             excess of 500 mL within a 56 day period.

          -  Pregnant females as determined by positive serum or urine hCG test at screening or
             prior to dosing.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Other exclusion criteria to be detailed at the time of physical screening by the
             Investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>10/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>29/03/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,WA</recruitmentstate>
    <hospital>GSK Investigational Site - Randwick</hospital>
    <hospital>GSK Investigational Site - Adelaide</hospital>
    <hospital>GSK Investigational Site - Nedlands</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      repeat ascending doses of GSK2018682. The study will also provide further evidence of the
      potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute
      Lymphocyte Counts (ALC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01431937</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>